TY - JOUR T1 - Kinetics of SARS-CoV-2 antibody responses pre-COVID-19 and post-COVID-19 convalescent plasma transfusion in patients with severe respiratory failure: an observational case–control study JF - Journal of Clinical Pathology JO - J Clin Pathol SP - 564 LP - 571 DO - 10.1136/jclinpath-2020-207356 VL - 75 IS - 8 AU - Matthew N Klein AU - Elizabeth Wenqian Wang AU - Paul Zimand AU - Heather Beauchamp AU - Caitlin Donis AU - Matthew D Ward AU - Aidaelis Martinez-Hernandez AU - Ali Tabatabai AU - John W Baddley AU - Evan M Bloch AU - Kristin E Mullins AU - Magali J Fontaine Y1 - 2022/08/01 UR - http://jcp.bmj.com/content/75/8/564.abstract N2 - Aims While the SARS-CoV-2 pandemic may be contained through vaccination, transfusion of convalescent plasma (CCP) from individuals who recovered from COVID-19 (CCP) is considered an alternative treatment. We investigate if CCP transfusion in patients with severe respiratory failure increases plasma titres of SARS-CoV-2 antibodies and improves clinical outcomes.Methods Patients with COVID-19 (n=34) were consented for CCP transfusion and serial blood draws pretransfusion and post-transfusion. Plasma SARS-CoV-2 antireceptor binding domain (RBD) IgG and IgM titres were measured by ELISA serially, and compared with serial plasma titre levels from control patients (n=68). The primary outcome was survival at 30 days, and secondary outcomes were length of ventilator and/or extracorporeal membrane oxygenation (ECMO) support, length of stay (LOS) in the hospital and in the intensive care unit (ICU). Outcomes were compared with matched control patients (n=34). Kinetics of antibodies and clinical outcomes were compared using LOess regression and ORs, respectively.Results Prior to CCP transfusion, 74% of patients were anti-RBD seropositive for IgG (median 1:3200), and 81% were anti-RBD IgM seropositive (median 1:320), while 16% were seronegative. The kinetics of antibody titres in CCP recipients were similar to controls. CCP recipients presented with similar survival, duration on ventilatory and/or ECMO support, as well as ICU and hospital LOS compared with controls.Conclusions CCP transfusion did not increase the kinetics of SARS-CoV2 antibodies and did not result in improved clinical outcomes in patients with COVID-19 with severe respiratory failure, suggesting that CCP may not be indicated in this category of patients.Data are available on reasonable request. ER -